Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 16 entries
Sorted by: Best Match Show Resources per page
The association of telomere length with colorectal cancer differs by the age of cancer onset.

Clinical and translational gastroenterology

Boardman LA, Litzelman K, Seo S, Johnson RA, Vanderboom RJ, Kimmel GW, Cunningham JM, Gangnon RE, Engelman CD, Riegert-Johnson DL, Potter J, Haile R, Buchanan D, Jenkins MA, Rider DN, Thibodeau SN, Petersen GM, Skinner HG.
PMID: 24598784
Clin Transl Gastroenterol. 2014 Mar 06;5:e52. doi: 10.1038/ctg.2014.3.

OBJECTIVES: Telomeres are nucleoprotein structures that cap the end of chromosomes and shorten with sequential cell divisions in normal aging. Short telomeres are also implicated in the incidence of many cancers, but the evidence is not conclusive for colorectal...

Cite
Boardman LA, Litzelman K, Seo S, et al. The association of telomere length with colorectal cancer differs by the age of cancer onset. Clin Transl Gastroenterol. 2014;5:e52doi: 10.1038/ctg.2014.3.
Boardman, L. A., Litzelman, K., Seo, S., Johnson, R. A., Vanderboom, R. J., Kimmel, G. W., Cunningham, J. M., Gangnon, R. E., Engelman, C. D., Riegert-Johnson, D. L., Potter, J., Haile, R., Buchanan, D., Jenkins, M. A., Rider, D. N., Thibodeau, S. N., Petersen, G. M., & Skinner, H. G. (2014). The association of telomere length with colorectal cancer differs by the age of cancer onset. Clinical and translational gastroenterology, 5e52. https://doi.org/10.1038/ctg.2014.3
Boardman, Lisa A, et al. "The association of telomere length with colorectal cancer differs by the age of cancer onset." Clinical and translational gastroenterology vol. 5 (2014): e52. doi: https://doi.org/10.1038/ctg.2014.3
Boardman LA, Litzelman K, Seo S, Johnson RA, Vanderboom RJ, Kimmel GW, Cunningham JM, Gangnon RE, Engelman CD, Riegert-Johnson DL, Potter J, Haile R, Buchanan D, Jenkins MA, Rider DN, Thibodeau SN, Petersen GM, Skinner HG. The association of telomere length with colorectal cancer differs by the age of cancer onset. Clin Transl Gastroenterol. 2014 Mar 06;5:e52. doi: 10.1038/ctg.2014.3. PMID: 24598784; PMCID: PMC3972691.
Copy Download .nbib Format: NLM
Targeted sequencing of established and candidate colorectal cancer genes in the Colon Cancer Family Registry Cohort.

Oncotarget

Raskin L, Guo Y, Du L, Clendenning M, Rosty C, Lindor NM, Gruber SB, Buchanan DD.
PMID: 29212164
Oncotarget. 2017 Jun 21;8(55):93450-93463. doi: 10.18632/oncotarget.18596. eCollection 2017 Nov 07.

The underlying genetic cause of colorectal cancer (CRC) can be identified for 5-10% of all cases, while at least 20% of CRC cases are thought to be due to inherited genetic factors. Screening for highly penetrant mutations in genes...

Cite
Raskin L, Guo Y, Du L, et al. Targeted sequencing of established and candidate colorectal cancer genes in the Colon Cancer Family Registry Cohort. Oncotarget. 2017;8(55):93450-93463doi: 10.18632/oncotarget.18596.
Raskin, L., Guo, Y., Du, L., Clendenning, M., Rosty, C., Lindor, N. M., Gruber, S. B., & Buchanan, D. D. (2017). Targeted sequencing of established and candidate colorectal cancer genes in the Colon Cancer Family Registry Cohort. Oncotarget, 8(55), 93450-93463. https://doi.org/10.18632/oncotarget.18596
Raskin, Leon, et al. "Targeted sequencing of established and candidate colorectal cancer genes in the Colon Cancer Family Registry Cohort." Oncotarget vol. 8,55 (2017): 93450-93463. doi: https://doi.org/10.18632/oncotarget.18596
Raskin L, Guo Y, Du L, Clendenning M, Rosty C, Lindor NM, Gruber SB, Buchanan DD. Targeted sequencing of established and candidate colorectal cancer genes in the Colon Cancer Family Registry Cohort. Oncotarget. 2017 Jun 21;8(55):93450-93463. doi: 10.18632/oncotarget.18596. eCollection 2017 Nov 07. PMID: 29212164; PMCID: PMC5706810.
Copy Download .nbib Format: NLM
Exploratory Genome-Wide Interaction Analysis of Nonsteroidal Anti-inflammatory Drugs and Predicted Gene Expression on Colorectal Cancer Risk.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology

Wang X, Su YR, Petersen PS, Bien S, Schmit SL, Drew DA, Albanes D, Berndt SI, Brenner H, Campbell PT, Casey G, Chang-Claude J, Gallinger SJ, Gruber SB, Haile RW, Harrison TA, Hoffmeister M, Jacobs EJ, Jenkins MA, Joshi AD, Li L, Lin Y, Lindor NM, Marchand LL, Martin V, Milne R, Maclnnis R, Moreno V, Nan H, Newcomb PA, Potter JD, Rennert G, Rennert H, Slattery ML, Thibodeau SN, Weinstein SJ, Woods MO, Chan AT, White E, Hsu L, Peters U.
PMID: 32651213
Cancer Epidemiol Biomarkers Prev. 2020 Sep;29(9):1800-1808. doi: 10.1158/1055-9965.EPI-19-1018. Epub 2020 Jul 10.

BACKGROUND: Regular use of nonsteroidal anti-inflammatory drugs (NSAID) is associated with lower risk of colorectal cancer. Genome-wide interaction analysis on single variants (G × E) has identified several SNPs that may interact with NSAIDs to confer colorectal cancer risk,...

Cite
Wang X, Su YR, Petersen PS, et al. Exploratory Genome-Wide Interaction Analysis of Nonsteroidal Anti-inflammatory Drugs and Predicted Gene Expression on Colorectal Cancer Risk. Cancer Epidemiol Biomarkers Prev. 2020;29(9):1800-1808doi: 10.1158/1055-9965.EPI-19-1018.
Wang, X., Su, Y. R., Petersen, P. S., Bien, S., Schmit, S. L., Drew, D. A., Albanes, D., Berndt, S. I., Brenner, H., Campbell, P. T., Casey, G., Chang-Claude, J., Gallinger, S. J., Gruber, S. B., Haile, R. W., Harrison, T. A., Hoffmeister, M., Jacobs, E. J., Jenkins, M. A., Joshi, A. D., Li, L., Lin, Y., Lindor, N. M., Marchand, L. L., Martin, V., Milne, R., Maclnnis, R., Moreno, V., Nan, H., Newcomb, P. A., Potter, J. D., Rennert, G., Rennert, H., Slattery, M. L., Thibodeau, S. N., Weinstein, S. J., Woods, M. O., Chan, A. T., White, E., Hsu, L., & Peters, U. (2020). Exploratory Genome-Wide Interaction Analysis of Nonsteroidal Anti-inflammatory Drugs and Predicted Gene Expression on Colorectal Cancer Risk. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 29(9), 1800-1808. https://doi.org/10.1158/1055-9965.EPI-19-1018
Wang, Xiaoliang, et al. "Exploratory Genome-Wide Interaction Analysis of Nonsteroidal Anti-inflammatory Drugs and Predicted Gene Expression on Colorectal Cancer Risk." Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology vol. 29,9 (2020): 1800-1808. doi: https://doi.org/10.1158/1055-9965.EPI-19-1018
Wang X, Su YR, Petersen PS, Bien S, Schmit SL, Drew DA, Albanes D, Berndt SI, Brenner H, Campbell PT, Casey G, Chang-Claude J, Gallinger SJ, Gruber SB, Haile RW, Harrison TA, Hoffmeister M, Jacobs EJ, Jenkins MA, Joshi AD, Li L, Lin Y, Lindor NM, Marchand LL, Martin V, Milne R, Maclnnis R, Moreno V, Nan H, Newcomb PA, Potter JD, Rennert G, Rennert H, Slattery ML, Thibodeau SN, Weinstein SJ, Woods MO, Chan AT, White E, Hsu L, Peters U. Exploratory Genome-Wide Interaction Analysis of Nonsteroidal Anti-inflammatory Drugs and Predicted Gene Expression on Colorectal Cancer Risk. Cancer Epidemiol Biomarkers Prev. 2020 Sep;29(9):1800-1808. doi: 10.1158/1055-9965.EPI-19-1018. Epub 2020 Jul 10. PMID: 32651213; PMCID: PMC7556991.
Copy Download .nbib Format: NLM
Dual role of allele-specific DNA hypermethylation within the TERT promoter in cancer.

The Journal of clinical investigation

Lee DD, Komosa M, Sudhaman S, Leão R, Zhang CH, Apolonio JD, Hermanns T, Wild PJ, Klocker H, Nassiri F, Zadeh G, Diplas BH, Yan H, Gallinger S, Pugh TJ, Ramaswamy V, Taylor MD, Castelo-Branco P, Nunes NM, Tabori U.
PMID: 34720085
J Clin Invest. 2021 Nov 01;131(21). doi: 10.1172/JCI146915.

Aberrant activation of telomerase in human cancer is achieved by various alterations within the TERT promoter, including cancer-specific DNA hypermethylation of the TERT hypermethylated oncological region (THOR). However, the impact of allele-specific DNA methylation within the TERT promoter on...

Cite
Lee DD, Komosa M, Sudhaman S, et al. Dual role of allele-specific DNA hypermethylation within the TERT promoter in cancer. J Clin Invest. 2021;131(21)doi: 10.1172/JCI146915.
Lee, D. D., Komosa, M., Sudhaman, S., Leão, R., Zhang, C. H., Apolonio, J. D., Hermanns, T., Wild, P. J., Klocker, H., Nassiri, F., Zadeh, G., Diplas, B. H., Yan, H., Gallinger, S., Pugh, T. J., Ramaswamy, V., Taylor, M. D., Castelo-Branco, P., Nunes, N. M., & Tabori, U. (2021). Dual role of allele-specific DNA hypermethylation within the TERT promoter in cancer. The Journal of clinical investigation, 131(21), . https://doi.org/10.1172/JCI146915
Lee, Donghyun D, et al. "Dual role of allele-specific DNA hypermethylation within the TERT promoter in cancer." The Journal of clinical investigation vol. 131,21 (2021). doi: https://doi.org/10.1172/JCI146915
Lee DD, Komosa M, Sudhaman S, Leão R, Zhang CH, Apolonio JD, Hermanns T, Wild PJ, Klocker H, Nassiri F, Zadeh G, Diplas BH, Yan H, Gallinger S, Pugh TJ, Ramaswamy V, Taylor MD, Castelo-Branco P, Nunes NM, Tabori U. Dual role of allele-specific DNA hypermethylation within the TERT promoter in cancer. J Clin Invest. 2021 Nov 01;131(21). doi: 10.1172/JCI146915. PMID: 34720085; PMCID: PMC8553568.
Copy Download .nbib Format: NLM
Targeted sequencing of 36 known or putative colorectal cancer susceptibility genes.

Molecular genetics & genomic medicine

DeRycke MS, Gunawardena S, Balcom JR, Pickart AM, Waltman LA, French AJ, McDonnell S, Riska SM, Fogarty ZC, Larson MC, Middha S, Eckloff BW, Asmann YW, Ferber MJ, Haile RW, Gallinger S, Clendenning M, Rosty C, Win AK, Buchanan DD, Hopper JL, Newcomb PA, Le Marchand L, Goode EL, Lindor NM, Thibodeau SN.
PMID: 28944238
Mol Genet Genomic Med. 2017 Jul 23;5(5):553-569. doi: 10.1002/mgg3.317. eCollection 2017 Sep.

BACKGROUND: Mutations in several genes predispose to colorectal cancer. Genetic testing for hereditary colorectal cancer syndromes was previously limited to single gene tests; thus, only a very limited number of genes were tested, and rarely those infrequently mutated in...

Cite
DeRycke MS, Gunawardena S, Balcom JR, et al. Targeted sequencing of 36 known or putative colorectal cancer susceptibility genes. Mol Genet Genomic Med. 2017;5(5):553-569doi: 10.1002/mgg3.317.
DeRycke, M. S., Gunawardena, S., Balcom, J. R., Pickart, A. M., Waltman, L. A., French, A. J., McDonnell, S., Riska, S. M., Fogarty, Z. C., Larson, M. C., Middha, S., Eckloff, B. W., Asmann, Y. W., Ferber, M. J., Haile, R. W., Gallinger, S., Clendenning, M., Rosty, C., Win, A. K., Buchanan, D. D., Hopper, J. L., Newcomb, P. A., Le Marchand, L., Goode, E. L., Lindor, N. M., & Thibodeau, S. N. (2017). Targeted sequencing of 36 known or putative colorectal cancer susceptibility genes. Molecular genetics & genomic medicine, 5(5), 553-569. https://doi.org/10.1002/mgg3.317
DeRycke, Melissa S, et al. "Targeted sequencing of 36 known or putative colorectal cancer susceptibility genes." Molecular genetics & genomic medicine vol. 5,5 (2017): 553-569. doi: https://doi.org/10.1002/mgg3.317
DeRycke MS, Gunawardena S, Balcom JR, Pickart AM, Waltman LA, French AJ, McDonnell S, Riska SM, Fogarty ZC, Larson MC, Middha S, Eckloff BW, Asmann YW, Ferber MJ, Haile RW, Gallinger S, Clendenning M, Rosty C, Win AK, Buchanan DD, Hopper JL, Newcomb PA, Le Marchand L, Goode EL, Lindor NM, Thibodeau SN. Targeted sequencing of 36 known or putative colorectal cancer susceptibility genes. Mol Genet Genomic Med. 2017 Jul 23;5(5):553-569. doi: 10.1002/mgg3.317. eCollection 2017 Sep. PMID: 28944238; PMCID: PMC5606870.
Copy Download .nbib Format: NLM
Genomic Characterization of Upper-Tract Urothelial Carcinoma in Patients With Lynch Syndrome.

JCO precision oncology

Donahu TF, Bagrodia A, Audenet F, Donoghue MTA, Cha EK, Sfakianos JP, Sperling D, Al-Ahmadie H, Clendenning M, Rosty C, Buchanan DD, Jenkins M, Hopper J, Winship I, Templeton AS, Walsh MF, Stadler ZK, Iyer G, Taylor B, Coleman J, Lindor NM, Solit DB, Bochner BH.
PMID: 30854504
JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.17.00143.

PURPOSE: Patients with Lynch syndrome (LS) have a significantly increased risk of developing upper-tract urothelial carcinoma (UTUC). Here, we sought to identify differences in the patterns of mutational changes in LS-associated versus sporadic UTUCs.PATIENTS AND METHODS: We performed targeted...

Cite
Donahu TF, Bagrodia A, Audenet F, et al. Genomic Characterization of Upper-Tract Urothelial Carcinoma in Patients With Lynch Syndrome. JCO Precis Oncol. 2018;2018doi: 10.1200/PO.17.00143.
Donahu, T. F., Bagrodia, A., Audenet, F., Donoghue, M. T. A., Cha, E. K., Sfakianos, J. P., Sperling, D., Al-Ahmadie, H., Clendenning, M., Rosty, C., Buchanan, D. D., Jenkins, M., Hopper, J., Winship, I., Templeton, A. S., Walsh, M. F., Stadler, Z. K., Iyer, G., Taylor, B., Coleman, J., Lindor, N. M., Solit, D. B., & Bochner, B. H. (2018). Genomic Characterization of Upper-Tract Urothelial Carcinoma in Patients With Lynch Syndrome. JCO precision oncology, 2018. https://doi.org/10.1200/PO.17.00143
Donahu, Timothy F, et al. "Genomic Characterization of Upper-Tract Urothelial Carcinoma in Patients With Lynch Syndrome." JCO precision oncology vol. 2018 (2018). doi: https://doi.org/10.1200/PO.17.00143
Donahu TF, Bagrodia A, Audenet F, Donoghue MTA, Cha EK, Sfakianos JP, Sperling D, Al-Ahmadie H, Clendenning M, Rosty C, Buchanan DD, Jenkins M, Hopper J, Winship I, Templeton AS, Walsh MF, Stadler ZK, Iyer G, Taylor B, Coleman J, Lindor NM, Solit DB, Bochner BH. Genomic Characterization of Upper-Tract Urothelial Carcinoma in Patients With Lynch Syndrome. JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.17.00143. PMID: 30854504; PMCID: PMC6404976.
Copy Download .nbib Format: NLM
Evaluating the utility of tumour mutational signatures for identifying hereditary colorectal cancer and polyposis syndrome carriers.

Gut

Georgeson P, Pope BJ, Rosty C, Clendenning M, Mahmood K, Joo JE, Walker R, Hutchinson RA, Preston S, Como J, Joseland S, Win AK, Macrae FA, Hopper JL, Mouradov D, Gibbs P, Sieber OM, O'Sullivan DE, Brenner DR, Gallinger S, Jenkins MA, Winship IM, Buchanan DD.
PMID: 33414168
Gut. 2021 Nov;70(11):2138-2149. doi: 10.1136/gutjnl-2019-320462. Epub 2021 Jan 07.

OBJECTIVE: Germline pathogenic variants (PVs) in the DNA mismatch repair (MMR) genes and in the base excision repair gene DESIGN: Whole-exome sequencing of formalin-fixed paraffin-embedded (FFPE) CRC tissue was performed on 33 MMR germline PV carriers, 12 biallelic RESULTS:...

Cite
Georgeson P, Pope BJ, Rosty C, et al. Evaluating the utility of tumour mutational signatures for identifying hereditary colorectal cancer and polyposis syndrome carriers. Gut. 2021;70(11):2138-2149doi: 10.1136/gutjnl-2019-320462.
Georgeson, P., Pope, B. J., Rosty, C., Clendenning, M., Mahmood, K., Joo, J. E., Walker, R., Hutchinson, R. A., Preston, S., Como, J., Joseland, S., Win, A. K., Macrae, F. A., Hopper, J. L., Mouradov, D., Gibbs, P., Sieber, O. M., O'Sullivan, D. E., Brenner, D. R., Gallinger, S., Jenkins, M. A., Winship, I. M., & Buchanan, D. D. (2021). Evaluating the utility of tumour mutational signatures for identifying hereditary colorectal cancer and polyposis syndrome carriers. Gut, 70(11), 2138-2149. https://doi.org/10.1136/gutjnl-2019-320462
Georgeson, Peter, et al. "Evaluating the utility of tumour mutational signatures for identifying hereditary colorectal cancer and polyposis syndrome carriers." Gut vol. 70,11 (2021): 2138-2149. doi: https://doi.org/10.1136/gutjnl-2019-320462
Georgeson P, Pope BJ, Rosty C, Clendenning M, Mahmood K, Joo JE, Walker R, Hutchinson RA, Preston S, Como J, Joseland S, Win AK, Macrae FA, Hopper JL, Mouradov D, Gibbs P, Sieber OM, O'Sullivan DE, Brenner DR, Gallinger S, Jenkins MA, Winship IM, Buchanan DD. Evaluating the utility of tumour mutational signatures for identifying hereditary colorectal cancer and polyposis syndrome carriers. Gut. 2021 Nov;70(11):2138-2149. doi: 10.1136/gutjnl-2019-320462. Epub 2021 Jan 07. PMID: 33414168; PMCID: PMC8260632.
Copy Download .nbib Format: NLM
Colorectal cancer and self-reported tooth agenesis.

Hereditary cancer in clinical practice

Lindor NM, Win AK, Gallinger S, Daftary D, Thibodeau SN, Silva R, Letra A.
PMID: 24607150
Hered Cancer Clin Pract. 2014 Mar 10;12(1):7. doi: 10.1186/1897-4287-12-7.

BACKGROUND: Germline mutations in APC and AXIN2 are both associated with colon neoplasia as well as anomalous dental development. We tested the hypothesis that congenitally missing teeth may occur more commonly in individuals diagnosed with colorectal cancer than in...

Cite
Lindor NM, Win AK, Gallinger S, et al. Colorectal cancer and self-reported tooth agenesis. Hered Cancer Clin Pract. 2014;12(1):7doi: 10.1186/1897-4287-12-7.
Lindor, N. M., Win, A. K., Gallinger, S., Daftary, D., Thibodeau, S. N., Silva, R., & Letra, A. (2014). Colorectal cancer and self-reported tooth agenesis. Hereditary cancer in clinical practice, 12(1), 7. https://doi.org/10.1186/1897-4287-12-7
Lindor, Noralane M, et al. "Colorectal cancer and self-reported tooth agenesis." Hereditary cancer in clinical practice vol. 12,1 (2014): 7. doi: https://doi.org/10.1186/1897-4287-12-7
Lindor NM, Win AK, Gallinger S, Daftary D, Thibodeau SN, Silva R, Letra A. Colorectal cancer and self-reported tooth agenesis. Hered Cancer Clin Pract. 2014 Mar 10;12(1):7. doi: 10.1186/1897-4287-12-7. PMID: 24607150; PMCID: PMC3975307.
Copy Download .nbib Format: NLM
Circulating Levels of Testosterone, Sex Hormone Binding Globulin and Colorectal Cancer Risk: Observational and Mendelian Randomization Analyses.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology

Dimou N, Mori N, Harlid S, Harbs J, Martin RM, Smith-Byrne K, Papadimitriou N, Bishop DT, Casey G, Colorado-Yohar SM, Cotterchio M, Cross AJ, Marchand LL, Lin Y, Offit K, Onland-Moret NC, Peters U, Potter JD, Rohan TE, Weiderpass E, Gunter MJ, Murphy N.
PMID: 33879453
Cancer Epidemiol Biomarkers Prev. 2021 Jul;30(7):1336-1348. doi: 10.1158/1055-9965.EPI-20-1690. Epub 2021 Apr 20.

BACKGROUND: Epidemiologic studies evaluating associations between sex steroid hormones and colorectal cancer risk have yielded inconsistent results. To elucidate the role of circulating levels of testosterone, and sex hormone-binding globulin (SHBG) in colorectal cancer risk, we conducted observational and...

Cite
Dimou N, Mori N, Harlid S, et al. Circulating Levels of Testosterone, Sex Hormone Binding Globulin and Colorectal Cancer Risk: Observational and Mendelian Randomization Analyses. Cancer Epidemiol Biomarkers Prev. 2021;30(7):1336-1348doi: 10.1158/1055-9965.EPI-20-1690.
Dimou, N., Mori, N., Harlid, S., Harbs, J., Martin, R. M., Smith-Byrne, K., Papadimitriou, N., Bishop, D. T., Casey, G., Colorado-Yohar, S. M., Cotterchio, M., Cross, A. J., Marchand, L. L., Lin, Y., Offit, K., Onland-Moret, N. C., Peters, U., Potter, J. D., Rohan, T. E., Weiderpass, E., Gunter, M. J., & Murphy, N. (2021). Circulating Levels of Testosterone, Sex Hormone Binding Globulin and Colorectal Cancer Risk: Observational and Mendelian Randomization Analyses. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 30(7), 1336-1348. https://doi.org/10.1158/1055-9965.EPI-20-1690
Dimou, Niki, et al. "Circulating Levels of Testosterone, Sex Hormone Binding Globulin and Colorectal Cancer Risk: Observational and Mendelian Randomization Analyses." Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology vol. 30,7 (2021): 1336-1348. doi: https://doi.org/10.1158/1055-9965.EPI-20-1690
Dimou N, Mori N, Harlid S, Harbs J, Martin RM, Smith-Byrne K, Papadimitriou N, Bishop DT, Casey G, Colorado-Yohar SM, Cotterchio M, Cross AJ, Marchand LL, Lin Y, Offit K, Onland-Moret NC, Peters U, Potter JD, Rohan TE, Weiderpass E, Gunter MJ, Murphy N. Circulating Levels of Testosterone, Sex Hormone Binding Globulin and Colorectal Cancer Risk: Observational and Mendelian Randomization Analyses. Cancer Epidemiol Biomarkers Prev. 2021 Jul;30(7):1336-1348. doi: 10.1158/1055-9965.EPI-20-1690. Epub 2021 Apr 20. PMID: 33879453.
Copy Download .nbib Format: NLM
How do researchers manage genetic results in practice? The experience of the multinational Colon Cancer Family Registry.

Journal of community genetics

Keogh LA, Fisher D, Sheinfeld Gorin S, Schully SD, Lowery JT, Ahnen DJ, Maskiell JA, Lindor NM, Hopper JL, Burnett T, Holter S, Arnold JL, Gallinger S, Laurino M, Esplen MJ, Sinicrope PS.
PMID: 23703702
J Community Genet. 2014 Apr;5(2):99-108. doi: 10.1007/s12687-013-0148-y. Epub 2013 May 24.

There is consensus internationally that research participants should be offered the opportunity to receive clinically relevant genetic information identified through research, but there is little empirical peer-reviewed work documenting this process. We report the experience of conducting genetic research...

Cite
Keogh LA, Fisher D, Sheinfeld Gorin S, et al. How do researchers manage genetic results in practice? The experience of the multinational Colon Cancer Family Registry. J Community Genet. 2013;5(2):99-108doi: 10.1007/s12687-013-0148-y.
Keogh, L. A., Fisher, D., Sheinfeld Gorin, S., Schully, S. D., Lowery, J. T., Ahnen, D. J., Maskiell, J. A., Lindor, N. M., Hopper, J. L., Burnett, T., Holter, S., Arnold, J. L., Gallinger, S., Laurino, M., Esplen, M. J., Sinicrope, P. S. (2014). How do researchers manage genetic results in practice? The experience of the multinational Colon Cancer Family Registry. Journal of community genetics, 5(2), 99-108. https://doi.org/10.1007/s12687-013-0148-y
Keogh, Louise A, et al. "How do researchers manage genetic results in practice? The experience of the multinational Colon Cancer Family Registry." Journal of community genetics vol. 5,2 (2014): 99-108. doi: https://doi.org/10.1007/s12687-013-0148-y
Keogh LA, Fisher D, Sheinfeld Gorin S, Schully SD, Lowery JT, Ahnen DJ, Maskiell JA, Lindor NM, Hopper JL, Burnett T, Holter S, Arnold JL, Gallinger S, Laurino M, Esplen MJ, Sinicrope PS. How do researchers manage genetic results in practice? The experience of the multinational Colon Cancer Family Registry. J Community Genet. 2014 Apr;5(2):99-108. doi: 10.1007/s12687-013-0148-y. Epub 2013 May 24. PMID: 23703702; PMCID: PMC3955463.
Copy Download .nbib Format: NLM
Phospholipase A2G1B polymorphisms and risk of colorectal neoplasia.

International journal of molecular epidemiology and genetics

Abbenhardt C, Poole EM, Kulmacz RJ, Xiao L, Curtin K, Galbraith RL, Duggan D, Hsu L, Makar KW, Caan BJ, Koepl L, Owen RW, Scherer D, Carlson CS, Potter JD, Slattery ML, Ulrich CM.
PMID: 24046806
Int J Mol Epidemiol Genet. 2013 Sep 12;4(3):140-9. eCollection 2013.

Pancreatic phospholipase A2, product of PLA2G1B, catalyzes the release of fatty acids from dietary phospholipids.Diet is the ultimate source of arachidonic acid in cellular phospholipids, precursor of eicosanoid signaling molecules, linked to inflammation, cell proliferation and colorectal carcinogenesis. We...

Cite
Abbenhardt C, Poole EM, Kulmacz RJ, et al. Phospholipase A2G1B polymorphisms and risk of colorectal neoplasia. Int J Mol Epidemiol Genet. 2013;4(3):140-9
Abbenhardt, C., Poole, E. M., Kulmacz, R. J., Xiao, L., Curtin, K., Galbraith, R. L., Duggan, D., Hsu, L., Makar, K. W., Caan, B. J., Koepl, L., Owen, R. W., Scherer, D., Carlson, C. S., Potter, J. D., Slattery, M. L., & Ulrich, C. M. (2013). Phospholipase A2G1B polymorphisms and risk of colorectal neoplasia. International journal of molecular epidemiology and genetics, 4(3), 140-9.
Abbenhardt, Clare, et al. "Phospholipase A2G1B polymorphisms and risk of colorectal neoplasia." International journal of molecular epidemiology and genetics vol. 4,3 (2013): 140-9.
Abbenhardt C, Poole EM, Kulmacz RJ, Xiao L, Curtin K, Galbraith RL, Duggan D, Hsu L, Makar KW, Caan BJ, Koepl L, Owen RW, Scherer D, Carlson CS, Potter JD, Slattery ML, Ulrich CM. Phospholipase A2G1B polymorphisms and risk of colorectal neoplasia. Int J Mol Epidemiol Genet. 2013 Sep 12;4(3):140-9. eCollection 2013. PMID: 24046806; PMCID: PMC3773565.
Copy Download .nbib Format: NLM
A Combined Proteomics and Mendelian Randomization Approach to Investigate the Effects of Aspirin-Targeted Proteins on Colorectal Cancer.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology

Nounu A, Greenhough A, Heesom KJ, Richmond RC, Zheng J, Weinstein SJ, Albanes D, Baron JA, Hopper JL, Figueiredo JC, Newcomb PA, Lindor NM, Casey G, Platz EA, Le Marchand L, Ulrich CM, Li CI, van Duijnhoven FJB, Gsur A, Campbell PT, Moreno V, Vodicka P, Vodickova L, Brenner H, Chang-Claude J, Hoffmeister M, Sakoda LC, Slattery ML, Schoen RE, Gunter MJ, Castellví-Bel S, Kim HR, Kweon SS, Chan AT, Li L, Zheng W, Bishop DT, Buchanan DD, Giles GG, Gruber SB, Rennert G, Stadler ZK, Harrison TA, Lin Y, Keku TO, Woods MO, Schafmayer C, Van Guelpen B, Gallinger S, Hampel H, Berndt SI, Pharoah PDP, Lindblom A, Wolk A, Wu AH, White E, Peters U, Drew DA, Scherer D, Bermejo JL, Williams AC, Relton CL.
PMID: 33318029
Cancer Epidemiol Biomarkers Prev. 2021 Mar;30(3):564-575. doi: 10.1158/1055-9965.EPI-20-1176. Epub 2020 Dec 14.

BACKGROUND: Evidence for aspirin's chemopreventative properties on colorectal cancer (CRC) is substantial, but its mechanism of action is not well-understood. We combined a proteomic approach with Mendelian randomization (MR) to identify possible new aspirin targets that decrease CRC risk.METHODS:...

Cite
Nounu A, Greenhough A, Heesom KJ, et al. A Combined Proteomics and Mendelian Randomization Approach to Investigate the Effects of Aspirin-Targeted Proteins on Colorectal Cancer. Cancer Epidemiol Biomarkers Prev. 2020;30(3):564-575doi: 10.1158/1055-9965.EPI-20-1176.
Nounu, A., Greenhough, A., Heesom, K. J., Richmond, R. C., Zheng, J., Weinstein, S. J., Albanes, D., Baron, J. A., Hopper, J. L., Figueiredo, J. C., Newcomb, P. A., Lindor, N. M., Casey, G., Platz, E. A., Le Marchand, L., Ulrich, C. M., Li, C. I., van Duijnhoven, F. J. B., Gsur, A., Campbell, P. T., Moreno, V., Vodicka, P., Vodickova, L., Brenner, H., Chang-Claude, J., Hoffmeister, M., Sakoda, L. C., Slattery, M. L., Schoen, R. E., Gunter, M. J., Castellví-Bel, S., Kim, H. R., Kweon, S. S., Chan, A. T., Li, L., Zheng, W., Bishop, D. T., Buchanan, D. D., Giles, G. G., Gruber, S. B., Rennert, G., Stadler, Z. K., Harrison, T. A., Lin, Y., Keku, T. O., Woods, M. O., Schafmayer, C., Van Guelpen, B., Gallinger, S., Hampel, H., Berndt, S. I., Pharoah, P. D. P., Lindblom, A., Wolk, A., Wu, A. H., White, E., Peters, U., Drew, D. A., Scherer, D., Bermejo, J. L., Williams, A. C., & Relton, C. L. (2021). A Combined Proteomics and Mendelian Randomization Approach to Investigate the Effects of Aspirin-Targeted Proteins on Colorectal Cancer. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 30(3), 564-575. https://doi.org/10.1158/1055-9965.EPI-20-1176
Nounu, Aayah, et al. "A Combined Proteomics and Mendelian Randomization Approach to Investigate the Effects of Aspirin-Targeted Proteins on Colorectal Cancer." Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology vol. 30,3 (2021): 564-575. doi: https://doi.org/10.1158/1055-9965.EPI-20-1176
Nounu A, Greenhough A, Heesom KJ, Richmond RC, Zheng J, Weinstein SJ, Albanes D, Baron JA, Hopper JL, Figueiredo JC, Newcomb PA, Lindor NM, Casey G, Platz EA, Le Marchand L, Ulrich CM, Li CI, van Duijnhoven FJB, Gsur A, Campbell PT, Moreno V, Vodicka P, Vodickova L, Brenner H, Chang-Claude J, Hoffmeister M, Sakoda LC, Slattery ML, Schoen RE, Gunter MJ, Castellví-Bel S, Kim HR, Kweon SS, Chan AT, Li L, Zheng W, Bishop DT, Buchanan DD, Giles GG, Gruber SB, Rennert G, Stadler ZK, Harrison TA, Lin Y, Keku TO, Woods MO, Schafmayer C, Van Guelpen B, Gallinger S, Hampel H, Berndt SI, Pharoah PDP, Lindblom A, Wolk A, Wu AH, White E, Peters U, Drew DA, Scherer D, Bermejo JL, Williams AC, Relton CL. A Combined Proteomics and Mendelian Randomization Approach to Investigate the Effects of Aspirin-Targeted Proteins on Colorectal Cancer. Cancer Epidemiol Biomarkers Prev. 2021 Mar;30(3):564-575. doi: 10.1158/1055-9965.EPI-20-1176. Epub 2020 Dec 14. PMID: 33318029; PMCID: PMC8086774.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 16 entries